Morgan Stanley
JUNO

Morgan Stanley’s Juno Therapeutics, Inc. JUNO Stock Holding History

Morgan Stanley’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,880,373
Closed -$86M – 6845
2017
Q4 		$86M Sell
1,880,373
-79,191
-4% -$3.95M 0.02% 664
2017
Q3 		$87.9M Buy
1,959,564
+510,912
+35% +$17.4M 0.03% 627
2017
Q2 		$43.3M Buy
1,448,652
+588,604
+68% +$14.5M 0.01% 997
2017
Q1 		$19.1M Sell
860,048
-101,139
-11% -$2.17M 0.01% 1617
2016
Q4 		$18.1M Sell
961,187
-105,560
-10% -$2.58M 0.01% 1638
2016
Q3 		$32M Sell
1,066,747
-82,755
-7% -$2.57M 0.01% 1108
2016
Q2 		$44.2M Sell
1,149,502
-105,463
-8% -$4.38M 0.02% 862
2016
Q1 		$47.8M Buy
1,254,965
+987,755
+370% +$34.4M 0.02% 776
2015
Q4 		$11.8M Sell
267,210
-623
-0.2% -$30.9K ﹤0.01% 1830
2015
Q3 		$10.9M Buy
267,833
+133,130
+99% +$5.84M ﹤0.01% 1867
2015
Q2 		$7.18M Buy
134,703
+33,059
+33% +$1.75M ﹤0.01% 2449
2015
Q1 		$6.17M Sell
101,644
-148,872
-59% -$7.22M ﹤0.01% 2548
2014
Q4 		$13.1M Buy
+250,516
New +$11.2M ﹤0.01% 1817

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Morgan Stanley's JUNO Position: Q1 2018 in Review

Morgan Stanley sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,880,373 shares — an estimated $86M sold.

Morgan Stanley first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $87.9M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Morgan Stanley reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Morgan Stanley sold 1,880,373 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $86M.
  • Morgan Stanley first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Morgan Stanley's Juno Therapeutics, Inc. position peaked at $87.9M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.